The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Another molecule called TAR-200 ... and is currently running phase 3 trials. Four years ago, Keytruda monotherapy was approved in NMIBC based on just a 41% CR rate. One other option besides ...

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.

The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, ...

Shares of Corvus Pharmaceuticals CRVS gained 13.9% on Sept. 10 after the company announced the initiation of a phase III ...

OmRx Oncology, or “OmRx,” a new biopharmaceutical venture with investment from Scripps Research, launched with a Phase 2 clinical asset in-licensed fr ...

Antennova, a clinical-stage biotech company focused on oncology today announced that it presented the latest data of CD73 ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...